Improving sensitivity of autoantibody testing for myasthenia gravis using cell-based assays: an evaluation of strategies that may be used in clinical practice - Report - MDSpire
Advertisement
Improving sensitivity of autoantibody testing for myasthenia gravis using cell-based assays: an evaluation of strategies that may be used in clinical practice
Clinical Report: Enhancing the Sensitivity of Autoantibody Detection in Myasthenia Gravis
Background
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness due to autoantibodies against acetylcholine receptors (AChR) and muscle-specific kinase (MuSK). Accurate detection of these autoantibodies is crucial for diagnosis and management. Current testing methods, including cell-based assays, are being evaluated for their effectiveness.
Data Highlights
Testing Method
Positive Results
Negative Results
Fixed CBA at 1:10 dilution
127 (13.1%)
843 (86.6%)
Repeat Fixed CBA
4 (5%)
74 (95%)
Send-out Live CBA
4 (31%)
9 (69%)
Fixed CBA at 1:5 dilution
4 (50%)
4 (50%)
Key Findings
Out of 973 patients tested, 127 (13.1%) were positive for autoantibodies using fixed CBA at 1:10 dilution.
Repeat testing after initially negative results yielded a 5% positivity rate.
Send-out live CBA identified autoantibodies in 31% of patients who were previously negative.
Testing at a lower dilution (1:5) resulted in 50% positivity among previously negative samples.
Overall, 94% of identified positive cases were detected on the initial fixed CBA.
Clinical Implications
The findings suggest that incorporating repeat testing and alternative dilution strategies may enhance the detection of autoantibodies in patients with suspected MG. Clinicians should consider these methods to improve diagnostic accuracy in challenging cases.
Conclusion
The study highlights the potential of various testing strategies to improve the sensitivity of autoantibody detection in myasthenia gravis, which may lead to better patient outcomes.
